Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Venous Thrombosis 2Venous Thromboembolism 2Lung Neoplasms 2Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡